family with sequence similarity 181 member BGenealiases: []
Q-omics provides the consensus-scored FAM181B profile across patient tissues and cancer cell-line models. FAM181B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, FAM181B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, FAM181B RNA expression shows 13,584 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, KIRC, and TGCT as cancer lineages where FAM181B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM181B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM181B survival associations across molecular data types. FAM181B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM181B RNA expression–survival associations across cancer types. High FAM181B expression shows favorable associations in PAAD, UVM, UCEC, BRCA, LUSC and CHOL. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify PAAD as the clearest survival context for FAM181B RNA expression.
This table summarizes FAM181B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM181B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM181B shows lower tumor expression in KIRC, KICH, THCA, COAD and KIRP and higher tumor expression in LUSC. The KIRC box plot shows higher FAM181B RNA expression in normal versus tumor tissue (log2 FC = −0.937, t-test p < 0.001).
This table shows molecular features associated with FAM181B in patient tissues and cancer cell lines. In patient samples, FAM181B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM181B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
